Once-Weekly Insulin Icodec Improves Time in Range, Glycemic Control Better than Daily Insulin Degludec

Data from a pair of phase 3a trials presented at ADA 2023 provide clinicians with new insight into the effects of once-weekly insulin icodec relative to daily insulin degludec.

Related Keywords

San Diego ,California ,United States ,University Of Texas Southwestern Medical Center ,Texas ,Dallas ,University Of Texas ,American ,Peter Odonnell Jr ,Florianmm Baeres ,Ildiko Lingvay ,Julio Rosenstock ,Diabetes Technology Society Julio Rosenstock ,Drug Administration ,Novo Nordisk ,Scientific Sessions Of The American Diabetes Association ,Global Medical Affairs At Novo Nordisk ,Division Of Endocrinology ,Velocity Clinical Research At Medical City Dallas ,School Of Public Health ,Diabetes Technology Society ,Scientific Sessions ,American Diabetes Association ,Velocity Clinical Research ,Medical City Dallas ,Texas Southwestern Medical ,Petero Donnell ,Public Health ,Global Medical Affairs ,Once Weekly Insulin Icodec ,Annual Scientific Sessions ,Glycemic Control ,Daily Insulin Degludec ,